Chemosensitive augmentation effect by combination treatment of vorinostat and arsenic trioxide in U266 cell line

Multiple myeloma (MM) is a disorder of terminally differentiated plasma cells characterized by clonal expansion in the bone marrow (BM). It is the second-most common hematologic malignancy. Many novel immunotherapy strategies, such as adoptive cell therapy and monoclonal antibodies, are currently under investigation in clinical trials, with encouraging outcomes in few of the strategies due to their positive impact on patient survival.1 Despite significant advances in therapeutic strategies, like new drugs and tandem auto-HSCT, are capable of enhancing the overall survival of the patients,2 MM still poses a challenge and remains a predominantly incurable disease and demands the need for the development of new treatment regimens for better insights of MM.3